ReviewBrain sciences2023
Endocannabinoid System and Exogenous Cannabinoids in Depression and Anxiety: A Review.
Review in Brain sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 2 syntheses or guidelines pooled it, 60 citations in OpenAlex.
- Genome-wide meta-analyses of non-response to antidepressants provide insights into underlying molecular genetics and suggest potential pharmacotherapies.Molecular psychiatry · 2026Pooled it
- Psychological Interventions for Cannabis Use among Adolescents and Young Adults: A Systematic Review.International journal of environmental research and public health · 2023Pooled it
- Exploring sex differences in endocannabinoid system biomarkers and their relationship with antidepressant treatment outcomes in major depressive disorder: a CAN-BIND 1 secondary analysis.European archives of psychiatry and clinical neuroscience · 2026Trial
- Circulating endocannabinoids in children and adolescents: associations with anxiety and the impact of selective serotonin reuptake inhibitors.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2025Trial
- MS-based metabolic profiling in serum for bipolar disorder.Metabolic brain disease · 2026Article
- Enhancing anandamide signalling through fatty acid amide hydrolase inhibition: An update on the pharmacological strategy for treating psychiatric disorders.Translational psychiatry · 2026Review
- Associations of cardiorespiratory fitness and muscular fitness with plasma levels of endocannabinoids and their analogues in adults with diagnosed depression: SONRIE study.European archives of psychiatry and clinical neuroscience · 2026Article
- Altered Plasma Endocannabinoids and Oxylipins in Adolescents with Major Depressive Disorders: A Case-Control Study.Nutrients · 2026Article
- Frequency of cannabis use and symptoms of anxiety and depression: a cross-sectional analysis of the Colorado cannabis users health cohort.Journal of cannabis research · 2025Article
- Differences in Cannabis and Cannabidiol Attitudes, Perceptions, and Behaviors Between US Adolescents Receiving Mood Disorder Treatment and Their Parents Across Legal Contexts.International journal of environmental research and public health · 2025Article
- Advances in cannabinoid receptors pharmacology: from receptor structural insights to ligand discovery.Acta pharmacologica Sinica · 2025Review
- Cannabis use and sleep problems among young adults by mental health status: A prospective cohort study.Addiction (Abingdon, England) · 2025Article
- Phytocannabinoids restore seizure-induced alterations in emotional behaviour in male rats.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2025Article
- Gastrodin Ameliorates Post-Stroke Depressive-Like Behaviors Through Cannabinoid-1 Receptor-Dependent PKA/RhoA Signaling Pathway.Molecular neurobiology · 2025Article
- Serum Lipidome Change in Japanese Patients with Major Depressive Disorder: A Real-World Exploratory Study.Neuropsychiatric disease and treatment · 2025Article
- Future Directions in Anxiolytic Therapy: A Comprehensive Review of Novel Targets and Strategies.Current neurovascular research · 2025Review
- Interactions between metabotropic glutamate and CB1 receptors: implications for mood, cognition, and synaptic signaling based on data from mGluR and CB1R-targeting drugs.Pharmacological reports : PR · 2024Review
- Endocannabinoid System and Metabolism: The Influences of Sex.International journal of molecular sciences · 2024Review
- Association between cannabis use and physical activity in the United States based on legalization and health status.Journal of cannabis research · 2024Article
- The Interplay of Exogenous Cannabinoid Use on Anandamide and 2-Arachidonoylglycerol in Anxiety: Results from a Quasi-Experimental Ad Libitum Study.Pharmaceuticals (Basel, Switzerland) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.